pharmacokinetics azlocillin child cystic fibrosis 6e1r2oxoimidazolidine1carboxamido2phenylacetamido penicillanic acid sodium salt azlocillin securopen given dos 100 200 mgkg body weight child cystic fibrosis intravenous bolus infection serum halflife 082 012 h lower dose 098 018 h higher dose consequent dose limited elimination kinetics due limitation renal nonrenal process elimination upon doubling dose 100 200 mgkg total body clearance dropped 1393 510 1h evaluation data presented publication indicate dose limited elimination kinetics normal situation azlocillin besides serum concentration patient cystic fibrosis considerably lower seen healthy state reason faster elimination renal route cystic fibrosis